Journal article
Avacopan: An Oral Complement 5a Inhibitor for ANCA-associated Vasculitis
Rheumatology, Vol.1(1), p.23
2022
DOI: 10.17925/RMD.2022.1.1.23
Abstract
The oral complement 5a receptor antagonist, avacopan, was recently studied in phase II and III clinical trials in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This article summarizes the study findings and considers the implications for future care of patients with AAV. Avacopan was proven to be safe and noninferior to glucocorticoids for AAV in a study where patients with severe newly diagnosed or relapsing AAV were initially treated with either rituximab or cyclophosphamide. Greater improvement in the glomerular filtration rate, reduced numbers of relapses and better health-related quality of life were observed in the avacopan group compared with the prednisone group. Patients in the avacopan group also had fewer glucocorticoid-associated adverse events and, despite complement inhibition, there were no cases of
Neisseria meningitidis
infection reported in either group. Future studies should address the long-term safety of avacopan and whether it can completely replace glucocorticoids in AAV-induction protocols and for the management of minor disease relapses.
Details
- Title: Subtitle
- Avacopan: An Oral Complement 5a Inhibitor for ANCA-associated Vasculitis
- Creators
- Matthew J MandellGatr-Alnada GherianiAleksander LenertPetar S Lenert
- Resource Type
- Journal article
- Publication Details
- Rheumatology, Vol.1(1), p.23
- DOI
- 10.17925/RMD.2022.1.1.23
- ISSN
- 2635-1420
- Grant note
- name: This article is published under the Creative Commons Attribution Non-commercial License.
- Language
- English
- Date published
- 2022
- Academic Unit
- Immunology; Internal Medicine
- Record Identifier
- 9984362289402771
Metrics
32 Record Views